475 related articles for article (PubMed ID: 27694501)
21. Systemic Mastocytosis: Clinical Update and Future Directions.
Tremblay D; Carreau N; Kremyanskaya M; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):728-38. PubMed ID: 26382091
[TBL] [Abstract][Full Text] [Related]
22. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
23. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
[TBL] [Abstract][Full Text] [Related]
24. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
25. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
Escribano L; Alvarez-Twose I; Sánchez-Muñoz L; Garcia-Montero A; Núñez R; Almeida J; Jara-Acevedo M; Teodósio C; García-Cosío M; Bellas C; Orfao A
J Allergy Clin Immunol; 2009 Sep; 124(3):514-21. PubMed ID: 19541349
[TBL] [Abstract][Full Text] [Related]
26. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
27. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review.
Stoecker MM; Wang E
Arch Pathol Lab Med; 2012 Jul; 136(7):832-8. PubMed ID: 22742558
[TBL] [Abstract][Full Text] [Related]
28. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
29. Mast cell leukemia.
Georgin-Lavialle S; Lhermitte L; Dubreuil P; Chandesris MO; Hermine O; Damaj G
Blood; 2013 Feb; 121(8):1285-95. PubMed ID: 23243287
[TBL] [Abstract][Full Text] [Related]
30. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.
Arock M; Akin C; Hermine O; Valent P
Eur J Haematol; 2015 Jun; 94(6):474-90. PubMed ID: 25753531
[TBL] [Abstract][Full Text] [Related]
31. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
Wang SA; Hutchinson L; Tang G; Chen SS; Miron PM; Huh YO; Jones DM; Bueso-Ramos C; Verstovsek S; Medeiros LJ; Miranda RN
Am J Hematol; 2013 Mar; 88(3):219-24. PubMed ID: 23440662
[TBL] [Abstract][Full Text] [Related]
32. Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.
Arock M; Wedeh G; Hoermann G; Bibi S; Akin C; Peter B; Gleixner KV; Hartmann K; Butterfield JH; Metcalfe DD; Valent P
Haematologica; 2018 Nov; 103(11):1760-1771. PubMed ID: 29976735
[TBL] [Abstract][Full Text] [Related]
33. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
34. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
[TBL] [Abstract][Full Text] [Related]
35. The genetic basis of mast cell activation disease - looking through a glass darkly.
Molderings GJ
Crit Rev Oncol Hematol; 2015 Feb; 93(2):75-89. PubMed ID: 25305106
[TBL] [Abstract][Full Text] [Related]
36. Systemic mastocytosis.
Ozdemir D; Dagdelen S; Erbas T
Am J Med Sci; 2011 Nov; 342(5):409-15. PubMed ID: 21629042
[TBL] [Abstract][Full Text] [Related]
37. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Gotlib J; Gerds AT; Bose P; Castells MC; Deininger MW; Gojo I; Gundabolu K; Hobbs G; Jamieson C; McMahon B; Mohan SR; Oehler V; Oh S; Padron E; Pancari P; Papadantonakis N; Pardanani A; Podoltsev N; Rampal R; Ranheim E; Rein L; Snyder DS; Stein BL; Talpaz M; Thota S; Wadleigh M; Walsh K; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2018 Dec; 16(12):1500-1537. PubMed ID: 30545997
[TBL] [Abstract][Full Text] [Related]
38. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
39. A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases.
Grifoni FI; Sciumè M; Pravettoni V; Ulivieri FM; Muratori S; Fracchiolla NS; Tagliaferri E; Gianelli U; Migliorini AC; Cro L; Pacilli A; Mannelli F; Baldini L
Hematol Oncol; 2019 Apr; 37(2):205-211. PubMed ID: 30849188
[TBL] [Abstract][Full Text] [Related]
40. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
